0001567619-22-005512.txt : 20220224
0001567619-22-005512.hdr.sgml : 20220224
20220224180559
ACCESSION NUMBER: 0001567619-22-005512
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220222
FILED AS OF DATE: 20220224
DATE AS OF CHANGE: 20220224
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Eichorn Laura G.
CENTRAL INDEX KEY: 0001861067
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40604
FILM NUMBER: 22673380
MAIL ADDRESS:
STREET 1: IMAGO BIOSCIENCES, INC.
STREET 2: 329 OYSTER POINT BLVD. 3RD FL
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Imago BioSciences, Inc.
CENTRAL INDEX KEY: 0001623715
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 454915810
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 329 OYSTER POINT BLVD., 3RD FLOOR
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 650 325 5156
MAIL ADDRESS:
STREET 1: 329 OYSTER POINT BLVD., 3RD FLOOR
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
doc1.xml
FORM 4
X0306
4
2022-02-22
0
0001623715
Imago BioSciences, Inc.
IMGO
0001861067
Eichorn Laura G.
C/O IMAGO BIOSCIENCES, INC.
329 OYSTER POINT BLVD, 3RD FLOOR
SOUTH SAN FRANCISCO
CA
94080
0
1
0
0
See Remarks
Common Stock
2022-02-22
4
M
0
8000
2.52
A
215737
D
Common Stock
2022-02-22
4
S
0
7600
21.5722
D
208137
D
Common Stock
2022-02-22
4
S
0
400
22.16
D
207737
D
Stock Option (Right to Buy)
2.52
2022-02-22
4
M
0
8000
0.00
D
2021-01-01
2027-03-28
Common Stock
8000
101956
D
Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.
The transaction was executed in multiple trades in prices ranging from $21.03 to $21.97, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
The transaction was executed in multiple trades in prices ranging from $22.07 to $22.21, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Chief Operating Officer/Interim CFO
/s/ Hugh Rienhoff, as Attorney-in-fact for Laura Eichorn
2022-02-24